Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSB | P07858 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 4/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18428026 | 0.88 | ATM (0.54) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL14421708 | 0.88 | ATM (0.54) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL18480443 | 0.87 | ATM (0.50) | ATMCTSSCTSKCTSBCTSL | |
| SCHEMBL3073448 | 0.85 | CTSS (0.47) | ATMCTSSCTSKCTSBCTSL | |
| SCHEMBL8370126 | 0.84 | ATM (0.71) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL4781275 | 0.84 | ATM (0.71) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL23273192 | 0.82 | ACE (0.64) | CTSSCTSKCTSBCTSLAPP | |
| SCHEMBL31689508 | 0.82 | CTSS (0.54) | ATMCTSSCTSKCTSBCTSL | |
| SCHEMBL23273193 | 0.82 | ACE (0.64) | CTSSCTSKCTSBCTSLAPP | |
| SCHEMBL31407446 | 0.82 | ACE (0.64) | CTSSCTSKCTSBCTSLAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187415-B2 | Sulfonamides as HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-11-17 | — | — | US | disclosed |
| US-20140018326-A1 | SULFONAMIDES AS HIB PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018326-A1 | SULFONAMIDES AS HIB PROTEASE INHIBITORS | PRSS1, PRSS3, PRSS2 | ATM 3994/4885SYK 4023/4885CTSS 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.